Hohlfeld R - Search Results

1

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R, Zamvil SS, Weber MS. Lalive PH, et al. Among authors: hohlfeld r. CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. CNS Drugs. 2011. PMID: 21476611 Free PMC article. Review.

2

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H, Hohlfeld R. Neuhaus O, et al. Among authors: hohlfeld r. Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7452-7. doi: 10.1073/pnas.97.13.7452. Proc Natl Acad Sci U S A. 2000. PMID: 10861011 Free PMC article.

3

[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment].

Wiendl H, Neuhaus O, Kappos L, Hohlfeld R. Wiendl H, et al. Among authors: hohlfeld r. Nervenarzt. 2000 Aug;71(8):597-610. doi: 10.1007/s001150050636. Nervenarzt. 2000. PMID: 10996910 Free PMC article. Review. German.

4

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells.

Farina C, Then Bergh F, Albrecht H, Meinl E, Yassouridis A, Neuhaus O, Hohlfeld R. Farina C, et al. Among authors: hohlfeld r. Brain. 2001 Apr;124(Pt 4):705-19. doi: 10.1093/brain/124.4.705. Brain. 2001. PMID: 11287371 Clinical Trial.

5

Mechanisms of action of glatiramer acetate in multiple sclerosis.

Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Neuhaus O, et al. Among authors: hohlfeld r. Neurology. 2001 Mar 27;56(6):702-8. doi: 10.1212/wnl.56.6.702. Neurology. 2001. PMID: 11288751 No abstract available.

6

Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Ziemssen T, Neuhaus O, Hohlfeld R. Ziemssen T, et al. Among authors: hohlfeld r. Drug Saf. 2001;24(13):979-90. doi: 10.2165/00002018-200124130-00005. Drug Saf. 2001. PMID: 11735654

7

[Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies].

Ziemssen T, Neuhaus O, Farina C, Hartung HP, Hohlfeld R. Ziemssen T, et al. Among authors: hohlfeld r. Nervenarzt. 2002 Apr;73(4):321-31. doi: 10.1007/s00115-001-1257-0. Nervenarzt. 2002. PMID: 12040979 Review. German.

8

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

Ziemssen T, Kümpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Ziemssen T, et al. Among authors: hohlfeld r. Brain. 2002 Nov;125(Pt 11):2381-91. doi: 10.1093/brain/awf252. Brain. 2002. PMID: 12390966

9

Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.

Weber MS, Starck M, Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Weber MS, et al. Among authors: hohlfeld r. Brain. 2004 Jun;127(Pt 6):1370-8. doi: 10.1093/brain/awh163. Epub 2004 Apr 16. Brain. 2004. PMID: 15090474

10

[Cannabinoids in multiple sclerosis. Opportunity or hazard?].

Neuhaus O, Kieseier BC, Klimke A, Gaebel W, Hohlfeld R, Hartung HP. Neuhaus O, et al. Among authors: hohlfeld r. Nervenarzt. 2004 Oct;75(10):1022-6. doi: 10.1007/s00115-004-1738-z. Nervenarzt. 2004. PMID: 15156287 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

433 results

Search Page

Filters